Trifecta vs. Magna for Aortic Valve Replacement. Differences in Clinical Outcome and Valve Hemodynamics
|
|
- Lorena Campbell
- 5 years ago
- Views:
Transcription
1 Circ J 2018; 82: doi: /circj.CJ ORIGINAL ARTICLE Cardiovascular Surgery Trifecta vs. Magna for Aortic Valve Replacement Differences in Clinical Outcome and Valve Hemodynamics Naoki Tadokoro, MD; Satsuki Fukushima, MD, PhD; Yusuke Shimahara, MD; Yorihiko Matsumoto, MD; Kizuku Yamashita, MD; Naonori Kawamoto, MD; Kimito Minami, MD, PhD; Junjiro Kobayashi, MD, PhD; Tomoyuki Fujita, MD, PhD Background: The number of surgical aortic valve replacements using bioprosthetic valves is increasing, and newer bioprosthetic valves may offer clinical advantages in Japanese patients, who generally require smaller replacement valves than Western patients. In this study we retrospectively evaluated the Trifecta and Magna valves to compare clinical outcomes and hemodynamics in a group of Japanese patients. Methods and Results: Data were retrospectively collected for 103 patients receiving a Trifecta valve and 356 patients receiving a Magna valve between June 2008 and Adverse events, outcomes, and valve hemodynamics were evaluated. There were no significant differences in early or late outcomes between the Trifecta and Magna groups. In the early postoperative period, mean (±SD) pressure gradient (9.0±3.1 vs. 13.8±4.8 mmhg; P<0.01) and effective orifice area (1.68±0.46 vs. 1.46±0.40 m 2 ; P<0.01) were significantly better for Trifecta, but the differences decreased over time. In particular, the interaction between time and valve type (Trifecta or Magna) was significantly different for mean pressure gradient between the 2 groups (P<0.01). Left ventricular mass regressed substantially in both groups, with no significant difference between them. There were no significant differences for severe patient-prosthesis mismatch. Conclusions: Postoperative outcomes were similar for both valves. An early hemodynamic advantage for the Trifecta valve lasted to approximately 1 year postoperatively but did not persist. Key Words: Aortic valve replacement; Bioprosthetic valve; Japan; Magna; Trifecta The number of surgical aortic valve replacements (AVRs) using a bioprosthesis is increasing according to the annual surveys of thoracic surgery by the Japanese association for thoracic surgery ( jpats.org/modules/investigation/index.php?content_id=7), which states that bioprostheses are used in three-quarters of all AVR procedures. In addition, the age limit for implantation of an aortic bioprosthesis is continuously being shifting down, 1 with bioprostheses used for AVR in 60% of sexagenarian patients and 90% of septuagenarian or octogenarian patients. 2 This may be related to the enhanced durability of new-generation bioprostheses, improved outcomes of redo valve replacement surgery, or the development of valve-in-valve (ViV) transcatheter aortic valve implantation. 3 The new-generation bioprostheses, including the Trifecta (St. Jude Medical, St. Paul, MN, USA) or the Carpentier- Edwards Perimount Magna or Magna Ease (Edwards Lifesciences, Irvine, CA, USA), reportedly have design advantages in terms of their large effective orifice area (EOA) and low pressure gradients, as well as in terms of the materials used, including anticalcification treatment, which potentially results in good hemodynamics and avoids patient-prosthesis mismatch. 4 In addition, the newgeneration bioprostheses have long-term durability. The valve leaflets of both the Trifecta and Magna prostheses are generated by glutaraldehyde-treated bovine pericardium but differ in their preparation and design. These fundamental differences may result in clinically prominent differences in their hemodynamics that should be considered particularly for Japanese patients, who have a small aortic annulus relative to their body size and require a smaller prosthesis than Western patients. 5 Therefore, the aims of this study were to review clinical outcomes at the National Cerebral and Cardiovascular Center after AVR using either valve and to compare the hemodynamic performance of each valve. Received June 27, 2018; revised manuscript received July 30, 2018; accepted August 3, 2018; released online September 15, 2018 Time for primary review: 23 days Department of Cardiovascular Surgery (N.T., S.F., Y.S., Y.M., K.Y., N.K., J.K., T.F.), Department of Surgical Intensive Care (K.M.), National Cerebral and Cardiovascular Center, Suita, Japan Mailing address: Tomoyuki Fujita, MD, PhD, Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Fujishirodai, Suita , Japan. tfujita@ncvc.go.jp ISSN All rights are reserved to the Japanese Circulation Society. For permissions, please cj@j-circ.or.jp
2 2768 TADOKORO N et al. Table 1. Patient Characteristics Trifecta (n=103) Magna (n=356) P-value Age (years) 72.9± ±9.9 <0.01 Sex (M/F) 49/54 213/ Body surface area (m 2 ) 1.57± ± Valve disease Aortic stenosis 63 (61.8) 217 (61.0) Aortic insufficiency 18 (17.6) 58 (16.3) Mixed 12 (11.8) 32 (9.0) Valve pathology Bicuspid aortic valve 23 (23.7) 103 (30.7) Degenerative/rheumatic 52 (53.6) 179 (53.1) Infective endocarditis 5 (4.9) 10 (2.8) Cardiac comorbidity Coronary stenosis 24 (23.5) 68 (19.1) History of PCI 4 (3.9) 22 (6.2) Atrial fibrillation 20 (19.4) 73 (20.5) Previous cardiac surgery 11 (10.7) 33 (9.3) Non-cardiac comorbidity Hypertension 80 (77.7) 272 (76.4) Hyperlipidemia 50 (48.5) 172 (48.3) 1.00 Diabetes 26 (25.2) 61 (17.1) Diabetes with insulin treatment 2 (1.9) 6 (1.7) 1.00 COPD 30 (29.1) 76 (21.3) Smoking 33 (32.0) 124 (34.8) HbA1c (%) 5.7± ± Prior stroke 13 (12.6) 26 (7.3) Carotid stenosis 5 (4.9) 11 (3.1) 0.37 Peripheral arterial disease 4 (3.9) 13 (3.7) 1.00 Chronic kidney disease 9 (8.7) 26 (7.3) Dialysis 1 (1.0) 7 (2.0) 0.69 NYHA class I 2 (1.9) 13 (3.7) II 83 (80.6) 307 (86.2) III 15 (14.5) 32 (9.0) IV 3 (2.9) 4 (1.1) BNP (pg/ml) 281± ± Preoperative echocardiography LVDd (mm) 51.1± ± LVDs (mm) 34.1± ± LVEF (%) 57.3± ± LVMI (g/m 2 ) 128.9± ± Preoperative AVA (cm 2 ) 0.79± ± Preoperative AVAi (cm 2 ) 0.50± ± Preoperative MPG (mmhg) 52.0± ± Risk score (%) EuroSCORE II 2.9± ± Data are presented as mean ± SD or n (%). AVA, aortic valve area; AVAi, aortic valve area index; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVDd, left ventricular internal diameter in diastole; LVDs, left ventricular internal diameter in systole; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; MPG, mean pressure gradient; NYHA, New York Heart Association; PCI, percutaneous coronary intervention. Methods Study Cohort and Data Collection This study was an observational single-center cohort study. The institutional surgical database contained a con- secutive series of 876 patients who underwent surgical AVR with a prosthetic valve at the National Cerebral and Cardiovascular Center between June 2008 and Mechanical prosthetic valves were implanted in 162 patients (18.5%), whereas the remaining 714 patients (81.5%)
3 Replacement Valve Choice in Japanese Patients 2769 Table 2. Intraoperative Variables Trifecta (n=103) Magna (n=356) P-value Procedure Isolated AVR 49 (48.0) 176 (49.4) MICS procedure 0 13 (3.7) Concomitant procedure Ascending aorta surgery 13 (12.7) 33 (9.3) Mitral valve surgery 15 (14.7) 58 (16.3) Tricuspid valve repair 9 (8.8) 27 (7.6) CABG 23 (22.5) 71 (19.9) Maze procedure 13 (12.7) 43 (12.1) Operation time (min) 312± ± ACC time (min) 104±36 101± CPB time (min) 147±46 147± Prosthesis size (mm) (35.0) 92 (25.8) (23.3) 112 (31.5) (34.0) 92 (25.8) (7.8) 39 (11.0) (5.9) Data are presented as mean ± SD or number (%). ACC, aortic cross-clamp time; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; MICS, minimally invasive cardiac surgery. underwent AVR with a stented bioprosthetic valve, such as the Trifecta (n=110 patients; 12.6%), Magna (n=374 patients; 42.7%), Mosaic (Medtronic, Minneapolis, MN, USA; n=185 patients; 21.1%), or Crown/Mitroflow (Sorin, Milan, Italy; n=45 patients; 5.1%) valves. Patients who underwent concomitant surgical procedures that potentially affected the clinical outcome and valve hemodynamics, such as septal myectomy or root enlargement, were excluded from this study. In addition, redo cases were excluded from the study because the aortic annulus, which is the critical structure in determining the hemodynamics of the prosthetic valve, is often deformed by the scar tissue and/or possibly by the surgical manipulation. Consequently, 103 patients with a Trifecta valve and 356 patients with Magna valve were evaluated in this study. Follow-up was completed for 102 patients (99.0%) with a Trifecta valve and 340 patients (95.5%) with a Magna valve. Data were collected by reviewing patients medical charts, surgical reports, and referral letters, supplemented by telephone interviews for patients under the care of distant physicians. Major adverse cardiac and cerebrovascular events (MACCE) were classified according to the standard definitions. 6 Events were classified as occurring early (within 30 days of implantation) or late (>31 days after implantation). Data collection was performed between January and February All patients gave written informed consent for surgery and the use of their data for diagnostic and research purposes prior to the surgery. The Institutional Review Board of the National Cerebral and Cardiovascular Center waived ethics compliance for this retrospective study. Patient Background and Characteristics Information regarding patient background and characteristics were retrieved from the medical charts. Prosthesis type and size were determined intraoperatively by individual surgeons as the best-matched prosthesis for each patient. In the Magna group, 134 patients (37.6%) received a Magna valve and 222 patients (62.4%) received the Magna Ease valve, which was introduced in the National Cerebral and Cardiovascular Center in 2011; the Trifecta valve was introduced in Patients in both groups underwent clinical and echocardiographic assessment preoperatively, on hospital discharge, 1 year postoperatively, and during follow-up (range 2 10 years). Surgical Indications, Procedure, and Postoperative Care Although the surgical indications for AVR were determined by the institutional heart team essentially according to recommended guidelines, 7,8 the prosthesis type was determined by the patient and their surgeon to select the best-matched type and size. As a result, there was no significant difference in patient background or characteristics between the Trifecta and Magna groups, with the exception of patient age at surgery (Table 1). The age difference may be secondary to the transcatheter ViV procedure, in which implantation is reportedly easier for the Magna than Trifecta valve. 9 Surgical AVR was performed via a median sternotomy in all patients in the Trifecta group and in 343 patients (96.3%) in the Magna group, whereas a minimally invasive approach, such as an upper partial sternotomy or right minithoracotomy, was used in 13 patients in the Magna group (Table 2). Prosthetic valve size or concomitant surgical procedures were not significantly different between the 2 groups. Postoperatively, aspirin 100 mg/day was given until the latest follow-up, whereas warfarin was given to a target international normalized ratio (INR) of for 3 months unless patients required anticoagulant therapy, such as those with atrial fibrillation. Following hospital discharge, patients were reassessed in the outpatient clinic or by a distant physician every 3 months until the latest follow-up.
4 2770 TADOKORO N et al. Table 3. Clinical Outcomes Trifecta (n=103) Magna (n=356) P-value Follow-up period (months) 31.0 [ ] 36.0 [ ] <0.01 Follow-up rate 102 (99.0) 340 (95.5) Early MACCE 2 (1.9) 7 (2.0) day mortality 1 (1.0) 1 (0.3) Cerebrovascular accidents (stroke) 0 2 (0.6) 1.00 Permanent pacemaker implant 0 3 (0.8) 1.00 Heart failure 1 (1.0) Perioperative myocardial infarction 0 1 (0.3) 1.00 Late MACCE 14 (13.6) 60 (16.9) Late mortality 4 (3.9) 17 (4.8) 1.00 Cardiac cause 0 4 (1.1) Cerebral hemorrhage 0 3 (0.8) 1.00 Pneumonia 2 (1.9) 4 (1.1) 0.62 Cancer 1 (1.0) 1 (0.3) Septic shock 0 1 (0.3) 1.00 Unknown cause 1 (0.9) 4 (1.1) 1.00 Cerebrovascular accidents (stroke) 2 (1.9) 13 (3.7) Permanent pacemaker implant 0 15 (4.2) Heart failure 4 (3.9) 9 (2.5) 0.5 Acute aortic dissection 0 3 (0.8) 1.00 Reintervention 2 (1.9) 8 (2.2) 1.00 SVD 0 1 (0.3) 1.00 PVE 2 (1.9) 6 (1.7) 1.00 PVL 0 1 (0.3) 1.00 Other operation 2 (1.9) 2 (0.6) 1.00 Data are presented as the median [interquartile range] or n (%). MACCE, major adverse cardiac and cerebrovascular event; PVE, prosthetic valve endocarditis; PVL, paravalvular leak; SVD, structural valve deterioration. Transthoracic Echocardiography All patients underwent the National Cerebral and Cardiovascular Center s standard 2-dimensional transthoracic echocardiography preoperatively, and 5 7 days after AVR; however, 82 patients (79.6%) in the Trifecta group and 251 patients (70.5%) in the Magna group underwent echocardiography 1-year after AVR. In addition, 58 patients (56.3%) in the Trifecta group and 181 patients (50.8%) in the Magna group underwent echocardiography at a mean interval from surgery of 35 months (range months) and 48 months (range months), respectively. Standard parameters were measured based on the recommendations of the American Society of Echocardiography. 10 Briefly, Doppler flow data were acquired from the left ventricular outflow tract just proximal to the prosthesis sewing ring. The modified Bernoulli equation was used to calculate peak and mean pressure gradient (MPG) across the prosthetic valve. EOA was calculated using a continuity equation on echo Doppler assessments. Patient-prosthesis mismatch, which was calculated as indexed EOA (ieoa)/ body surface area, was classified as not clinically significant (ieoa >1 cm 2 /m 2 ), mild (ieoa cm 2 /m 2 ), moderate (ieoa cm 2 /m 2 ), or severe (ieoa <0.65 cm 2 /m 2 ). 11 Left ventricular mass (LVM; g) was calculated using the following formula and indexed to body surface area (LMVi): LVM (g)=0.8 (1.04 ([LVDd+PWTd+ISTd] 3 LVDd 3 ))+0.6 where LVDd is left ventricular internal diameter in dias- tole, PWTd is posterior wall thickness in diastole, and ISTd is interventricular septum thickness in diastole. The effect of LVMi regression was evaluated by comparing preoperative values with those in each postoperative period (at discharge, 1 year postoperatively, and follow-up). The measured parameters were recorded in the official echocardiographic report, which was retrieved as data for this study. Statistical Analysis Continuous variables are presented as the mean ± SD, whereas categorical variables are presented as frequencies and percentages. Survival and event-free survival rates were calculated using the Kaplan-Meier method with 95% confidence intervals (CIs). Hemodynamic primary endpoints were interactions between time points (discharge, 1 year postoperatively, and at each follow-up) and valve type (Trifecta vs. Magna) for MPG, EOA, and LVMi after adjusting for the following baseline characteristics: age, sex, body surface area, valve size, history of hypertension, dyslipidemia, diabetes, chronic kidney disease, atrial fibrillation, coronary artery disease, carotid artery stenosis, prior stroke, peripheral arterial disease, smoking habit, preoperative New York Heart Association class, 12 preoperative European System for Cardiac Operative Risk Evaluation (EuroSCORE), 13 preoperative ejection fraction, preoperative stroke volume, type of valve disease, tricuspid valve, bicuspid valve, and etiology of the valve disease. Linear model estimation using ordinary least
5 Replacement Valve Choice in Japanese Patients 2771 squares and the Huber-White method was used to adjust the variance covariance matrix of a fit from least squares to correct for heteroscedasticity and for correlated responses from patients. A multivariate covariance analysis model was constructed to further compare the primary study endpoints (MPG, EOA, and LVMi) at the 1-year follow-up. The second endpoint was analysis of the overall survival and freedom from MACCE, using the preoperative variables for the regression analysis. A validated statistical linear mixed model was used to analyze the effect of each prosthetic valve function (the hemodynamic parameters). Continuous variables without repeated measures were tested using an unpaired t-test, whereas continuous variables with repeated measures were tested using a paired t-test; ordinal variables were tested using the Mann-Whitney U-test. Categorical variables were tested using the Chi-squared test, and 2-sided statistics were performed with significance set at a level of Statistical analyses were performed using R (R Foundation for Statistical Computing, Vienna, Austria). Results Outcomes at 30 Days Either Trifecta (n=103) or Magna (n=356) valves were used for AVR in patients in this study. One patient died in each group from thromboembolic events within 30 days postoperatively (Table 3). Cerebrovascular accidents occurred in 2 patients (0.6%) in the Magna group, whereas new permanent pacemaker implantation was performed for complete atrioventricular block in 3 patients (0.8%) in the Magna group. Perioperative myocardial infarction occurred in 1 patient in the Magna group. In this patient, thromboembolic occlusion of the left anterior descending artery occurred 12 h after the end of surgery, which was successfully treated by transcatheter thrombectomy. As a result, there was no significant difference in the 30-day outcome between the 2 groups. Long-Term Outcomes Patient follow-up was completed at the end of the study in 102 patients (99.0%) in the Trifecta group and in 340 patients (95.5%) in the Magna group (P=0.09), with a mean follow-up of 31.0 months (range months) and 36.0 months (range months), respectively (P<0.01). This significant difference is explained by the fact that the Magna valve was market released prior to the Trifecta valve. As a result, there were 4 deaths (3.9%) in the Trifecta group and 17 deaths (4.8%) in the Magna group by the end of the study. Actuarial survival in the Trifecta group was 99.0% at 1 year and 93.5% at 3 years, whereas in the Magna group it was 98.5% at 1 year and 96.3% at 3 years (log-rank, P=0.263; Figure 1A). Long-term MACCE included cerebrovascular accidents in 2 patients (1.9%) in the Trifecta group and in 13 patients (3.7%) in the Magna group. A permanent pacemaker was implanted after discharge in 15 patients in the Magna group only. Prosthetic valve endocarditis was diagnosed in 2 patients (1.9%) in the Trifecta group and in 6 patients (1.7%) in the Magna group. One patient in the Magna group experienced structural valve deterioration. As a result, freedom from MACCE in the Trifecta group was 93.9% at 1 year and 79.9% at 3 years, whereas in the Magna group it was 94.1% at 1 year and 82.0% at 3 years (log rank, P=0.662; Figure 1B). There was no significant Figure 1. Long-term (A) survival and (B) freedom from major adverse cardiac and cerebrovascular events after aortic valve replacement with the Trifecta and Magna valves assessed using the Kaplan-Meier method and compared using the logrank test. difference in the incidence of MACCE between the 2 groups using logistic regression analysis (odds ratio [OR] 1.26; P=0.434) and proportional odds regression analysis (OR 1.27; P=0.413). Difference in Valve Hemodynamics: Trifecta vs. Magna All patients underwent transthoracic echocardiography preoperatively, at discharge, and annually thereafter. Unadjusted average MPG for all valve sizes at discharge was significantly lower in the Trifecta than Magna group (9.0±3.1 vs. 13.8±4.8 mmhg, respectively; P<0.01). One year postoperatively, mean MPG for all sizes was significantly lower in the Trifecta than Magna group (10.9±3.8 vs. 12.7±5.3 mmhg, respectively; P<0.01), whereas there was no significant difference in MPG for 19-, 21-, and 25-mm valves at 1 year between the 2 groups. There was also no significant difference in MPG for all valve sizes between the 2 groups at the latest follow-up (11.1±4.1 vs. 12.4±4.6 mmhg in the Trifecta and Magna groups, respectively; P=0.062, Figure 2A). Interactions between time points (discharge, 1 year postoperatively, and at the latest follow-up) and valve type (Trifecta or Magna) for MPG were significantly different between the 2 groups (P<0.01), indicating that MPG was significantly lower in the Trifecta group soon after surgery, but thereafter the difference between groups was smaller (Figure 2B).
6 2772 TADOKORO N et al. Figure 2. Transthoracic echocardiographic assessment of the mean pressure gradient (MPG) for each valve: (A) unadjusted (actual) data and (B) interaction between time points (at discharge, 1 year postoperatively, at follow-up) and valve type (Trifecta vs. Magna). EOA showed a consistent trend regarding MPG (Figure 3A). Average EOA for all valve sizes at discharge was significantly larger in the Trifecta than Magna group (1.68±0.46 vs. 1.46±0.40 cm 2, respectively; P<0.01), whereas average EOA for each valve size was significantly larger for the Trifecta than Magna group. One-year postoperatively, mean EOA for all valve sizes was significantly larger in the Trifecta than Magna group (1.64±0.40 vs. 1.50±0.42 cm 2, respectively; P=0.01), whereas there was no significant difference in the EOA for the 23- or 25-mm valves between the 2 groups. At the latest follow-up, there was a significant difference in EOA only for the 21-mm valve. Interestingly, EOA in the Magna group remained unchanged, whereas that of the Trifecta group appeared to decrease over the study period (Figure 3B). There was no significant difference in EOA between the 2 groups over the study period. LVM Regression LVM was calculated based on transthoracic echocardiographic data. The LVMi regression rate was defined by the ratio of LVMi at each time point to preoperative LVMi. There was a steady decrease in LVMi in both groups over the study period, reaching a 25±29.1% and 29.1±18.8% reduction in the Trifecta and Magna groups, respectively (Figure 4A). LVMi reduction appeared to predominate in the Magna compared with Trifecta group, although the difference was not statistically significant (Figure 4B). Patient-Prosthesis Mismatch After AVR There was no significant difference in the incidence of severe patient-prosthesis mismatch in either group over the study period. Severe patient-prosthesis mismatch was observed in 5 patients (4.8%) in the Trifecta group and in 38 patients (10.7%) in the Magna group at discharge (log-
7 Replacement Valve Choice in Japanese Patients 2773 Figure 3. Transthoracic echocardiographic assessment of the effective orifice area (EOA) for each valve: (A) unadjusted (actual) data and (B) interaction between time points (at discharge, 1 year postoperatively, at follow-up) and valve type (Trifecta vs. Magna). rank test, P=0.0595), in 3 (2.9%) and 21 (5.9%) patients, respectively, at 1 year (log-rank test, P=0.218), and in 3 (2.9%) and 20 (5.6%) patients, respectively, at the latest follow-up (log-rank test, P=0.211). Discussion This study compared institutional clinical and hemodynamic outcomes after AVR using Trifecta and Magna bioprostheses. Neither in-hospital nor midterm clinical outcomes were significantly different when comparing the 2 valves because patient characteristics and surgical procedures did not differ significantly, including the size of the prosthesis selected. Echocardiographically, MPG across the prosthetic valve was significantly lower in the Trifecta than Magna group soon after surgery; however, this differ- ence decreased over the study period. EOA of the prosthetic valve showed a similar trend to MPG soon after surgery, with no significant difference in EOA between the groups over the study period. LVM regressed substantially in both groups, with no significant difference in the degree of regression between the 2 groups over the study period. In addition, there was no significant difference in the incidence of severe patient-prosthesis mismatch between the groups over the study period. A hemodynamic advantage was echocardiographically more prominent for the Trifecta than Magna valve soon after surgery. We attributed this to the design of the valves, with the valve leaflets mounted outside the sewing ring on the Trifecta valve and inside the sewing ring on the Magna valve, which created a larger orifice area on the Trifecta valve. This hemodynamic advantage gradually diminished
8 2774 TADOKORO N et al. Figure 4. Transthoracic echocardiographic assessment of left ventricular mass index (LVMi) for each valve: (A) unadjusted (actual) data and (B) interaction between time points (at discharge, 1 year postoperatively, at follow-up) and valve type (Trifecta vs. Magna). over time, and was related, at least in part, to an immunological reaction with the deposition of platelets and subsequent fibrin formation with leaflet thickening and pannus formation. 14 However, further follow-up and/or an in vivo study are required to prove this theory. One may claim that the hemodynamic advantage of the Trifecta valve was not reflected in our clinical outcomes regarding the degree of LVM regression or patient-prosthesis mismatch. Possible reasons for this are the small number of patients and/or, possibly more importantly, the relatively short period of the hemodynamic advantage, which was insufficient to produce substantial differences in the outcomes, including LVM regression, even in Japanese patients, and the relatively small size of the prosthesis compared with those used in Western patients. Redo valve surgery may be required in patients undergoing bioprosthetic valve replacement, and the aortic ViV procedure is an option in these patients. Therefore, it is important to select the valve prosthesis while considering possible future aortic ViV. Because the Trifecta valve has externally mounted leaflets with a rigid sewing cuff, aortic ViV with a Trifecta valve reportedly has the following disadvantages: (1) expanding the externally mounted Trifecta leaflets potentially obstructs the coronary artery ostia; 9 and (2) ViV then requires a smaller transcatheter heart valve size than the implanted valve, which has a rigid sewing cuff that cannot be broken by balloon expansion. In fact, it was reported that aortic ViV with the 26-mm Sapien XT (Edwards Lifesciences) over a 25-mm Trifecta valve led to significantly high coronary obstruction rates compared with the 23-mm Sapien XT, 15 although some reports state that aortic ViV was safely performed over the 23-mm Trifecta valve using a St. Jude Medical Portico 23-mm valve or a 23-mm Medtronic Core-Valve Evolut valve (Medtronic). 16,17 In contrast, obstruction of the coronary ostia reportedly rarely occurs with aortic ViV over a Magna valve, in which the leaflets are mounted internally. Previous reports also state that it is possible to fracture the sewing cuff of the Magna valve with the high-pressure balloon to accept a 1-mm larger transcatheter heart valve than the labeled valve size, ex vivo. 18 Therefore, it is reasonable to suggest the Magna valve for patients who are likely to
9 Replacement Valve Choice in Japanese Patients 2775 need a second valve replacement surgery. This study is limited by its retrospective design. In addition, prosthetic valve selection (Trifecta vs. Magna) was not randomized, but instead was determined by individual surgeons who implanted the best-matched valve prosthesis for each patient. Selection bias may be minimal because there was no significant difference in patient background and characteristics between the 2 groups. Postoperative follow-up periods also significantly differed between the 2 groups, potentially introducing analytical bias. However, the patients background and characteristics and the surgical procedures, including prosthesis size, were almost identical between the 2 groups. In addition, we used appropriate statistical methods, such as the validated statistical linear mixed model, to eliminate potential bias related to different follow-up periods. Conclusions In conclusion, post-avr clinical outcomes, including LVM regression and patient prosthesis mismatch, did not differ significantly between the Trifecta and Magna valves. Although hemodynamic performance of the valve prosthesis was greater for the Trifecta valve at least until 1-year after AVR, this difference diminished gradually over time. Acknowledgment The authors thank Jane Charbonneau (Edanz Group; www. edanzediting.com/ac) for the English language editing of a draft of this manuscript. Sources of Funding This work was not supported by a specific grant from any funding agency in the public, commercial, or not-for-profit sectors. None declared. Conflict of Interest References 1. Kaneko T, Cohn LH, Aranki SF. Tissue valve is the preferred option for patients aged 60 and older. Circulation 2013; 128: Nakano K, Hirahara N, Motomura N, Miyata H, Takamoto S. Current status of cardiovascular surgery in Japan, 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database. 4. Valvular heart surgery. Gen Thorac Cardiovasc Surg 2017; 66: Gozdek M, Raffa GM, Suwalski P, Kolodziejczak M, Anisimowicz L, Kubica J, et al. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: Systematic review and meta-analysis. Eur J Cardiothorac Surg 2017; 53: Dumesnil JG, Pibarot P. Prosthesis-patient mismatch: An update. Curr Cardiol Rep 2011; 13: Sakamoto Y, Hashimoto K. Update on aortic valve prosthesispatient mismatch in Japan. Gen Thorac Cardiovasc Surg 2013; 61: Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL, et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg 2008; 135: Bonow RO, Brown AS, Gillam LD, Kapadia SR, Kavinsky CJ, Lindman BR, et al. ACC/AATS/AHA/ASE/EACTS/HVS/SCA/ SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for the Treatment of Patients With Severe Aortic Stenosis: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Valve Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Soc Echocardiogr 2018; 31: Haude M. Management of valvular heart disease: ESC/EACTS guidelines Herz 2017; 42: (in German). 9. Ribeiro HB, Rodes-Cabau J, Blanke P, Leipsic J, Kwan Park J, Bapat V, et al. Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: Insights from the VIVID registry. Eur Heart J 2017; 39: Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA, et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: A report from the American Society of Echocardiography s Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009; 22: Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: Definition, clinical impact, and prevention. Heart 2006; 92: Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1 e Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg 2012; 41: Goldman S, Cheung A, Bavaria JE, Petracek MR, Groh MA, Schaff HV. Midterm, multicenter clinical and hemodynamic results for the Trifecta aortic pericardial valve. J Thorac Cardiovasc Surg 2017; 153: e Stock S, Scharfschwerdt M, Meyer-Saraei R, Richardt D, Charitos EI, Sievers HH, et al. Does undersizing of transcatheter aortic valve bioprostheses during valve-in-valve implantation avoid coronary obstruction?: An in vitro study. Thorac Cardiovasc Surg 2017; 65: Haussig S, Schuler G, Linke A. Treatment of a failing St. Jude Medical Trifecta by Medtronic Corevalve Evolut valve-in-valve implantation. JACC Cardiovasc Interv 2014; 7: e81 e Kim WK, Kempfert J, Walther T, Mollmann H. Transfemoral valve-in-valve implantation of a St. Jude Medical Portico in a failing Trifecta bioprosthesis: A case report. Clin Res Cardiol 2015; 104: Allen KB, Chhatriwalla AK, Cohen DJ, Saxon JT, Aggarwal S, Hart A, et al. Bioprosthetic valve fracture to facilitate transcatheter valve-in-valve implantation. Ann Thorac Surg 2017; 104:
Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationHow to Avoid Prosthesis-Patient Mismatch
How to Avoid Prosthesis-Patient Mismatch Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC
More informationManagement of Difficult Aortic Root, Old and New solutions
Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationInterventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504
Transcatheter valve-in-valve e implantation for aortic bioprosthetic valve dysfunction Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504 Your responsibility This
More informationHemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves
Hemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves Speaker's name: I have the following potential conflicts of interest to report: Proctorship for Medtronic Agenda Failure modes
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationTAVI Versus Suturless Valve In Intermediate Risk Patients
TAVI Versus Suturless Valve In Intermediate Risk Patients Walid Abukhudair FRCSc President of Saudi Society for Cardiac Surgeons Head of Cardiac Surgery in KFAFH Background AS is the most frequent cardiac
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationAnn Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article
Ann Thorac Cardiovasc Surg 2015; 21: 53 58 Online April 18, 2014 doi: 10.5761/atcs.oa.13-00364 Original Article The Impact of Preoperative and Postoperative Pulmonary Hypertension on Long-Term Surgical
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationTranscatheter valve-in-valve implantation for degenerated surgical bioprostheses
Review Article Transcatheter valve-in-valve implantation for degenerated surgical bioprostheses Dale J. Murdoch, John G. Webb Centre for Heart Valve Innovation, St. Paul s Hospital, Vancouver, Canada Contributions:
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationMagdalena Erlebach 1, Michael Wottke 1, Marcus-André Deutsch 1, Markus Krane 1, Nicolo Piazza 2, Ruediger Lange 1, Sabine Bleiziffer 1
Original Article on TAVI Redo aortic valve surgery versus transcatheter valve-in-valve implantation for failing surgical bioprosthetic valves: consecutive patients in a single-center setting Magdalena
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationRole of Sutureless Valves in the Surgeon s Armamentarium Prof. Dr Malakh Shrestha Vice Chair, Director of Aortic Surgery Cardiothoracic,
Role of Sutureless Valves in the Surgeon s Armamentarium Prof. Dr Malakh Shrestha Vice Chair, Director of Aortic Surgery Cardiothoracic, transplantation and Vascular Surgery Hannover Medical School, Germany
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/28521 holds various files of this Leiden University dissertation Author: Katsanos, Spyridon Title: Outcomes of transcatheter aortic valve implantation Issue
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationTissue vs Mechanical What s the Data??
Biological (Tissue) Valve in a 60 year old patient: Debate Tissue vs Mechanical What s the Data?? Joseph E. Bavaria, MD Immediate-Past President - Society of Thoracic Surgeons (STS) Brooke Roberts-William
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationPresenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose
Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material
More informationDurability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement
Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Masaki Hamamoto, MD, Ko Bando, MD, Junjiro Kobayashi, MD, Toshihiko Satoh, MD, MPH, Yoshikado
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationTranscatheter Aortic Valve Implantation in Patients With Concomitant Mitral and Tricuspid Regurgitation
Transcatheter Aortic Valve Implantation in Patients With Concomitant Mitral and Tricuspid Regurgitation Andrea Hutter, MD, Sabine Bleiziffer, MD, PhD, Valerie Richter, MS, Anke Opitz, MD, Ina Hettich,
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationProf. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM
The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationAppropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y.
Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y. Szeto, MD on behalf of The PARTNER Trial Investigators and The PARTNER
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationTransapical Transcatheter Aortic Valve Implantation in the Presence of a Mitral Prosthesis
Journal of the American College of Cardiology Vol. 58, No. 7, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.023
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationProsthesis-Patient Mismatch or Prosthetic Valve Stenosis?
EuroValves 2015, Nice Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis? Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE FESC Canada Research Chair in Valvular Heart Diseases Université LAVAL Disclosure
More informationOutcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property
More informationClinical predictors of prosthesis-patient mismatch after aortic valve replacement for aortic stenosis
CLINICS 2012;67(1):55-60 DOI:10.6061/clinics/2012(01)09 CLINICAL SCIENCE Clinical predictors of prosthesis-patient mismatch after aortic valve replacement for aortic stenosis Luis M. Astudillo, I Orlando
More informationKinsing Ko, Thom de Kroon, Najim Kaoui, Bart van Putte, Nabil Saouti. St. Antonius Hospital, Nieuwegein, The Netherlands
Minimal Invasive Mitral Valve Surgery After Previous Sternotomy Without Aortic Clamping: Short- and Long Term Results of a Single Surgeon Single Institution Kinsing Ko, Thom de Kroon, Najim Kaoui, Bart
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationA 20-year experience of 1712 patients with the Biocor porcine bioprosthesis
Acquired Cardiovascular Disease Mykén and Bech-Hansen A 2-year experience of 1712 patients with the Biocor porcine bioprosthesis Pia S. U. Mykén, MD, PhD, a and Odd Bech-Hansen, MD, PhD b Objective: The
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationTreatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques
Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques Pablo Codner, Abid Assali, Hanna Vaknin-Assa, Katia Orvin, Ram Sharony, Leor Perl, Gabriel Greenberg, Marina Kupershmidt,
More informationPeri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)
Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY) Thomas Walther, Christian W. Hamm, Gerhard Schuler, Alexander Berkowitsch,
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More informationIntroducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
More informationMitral Gradients and Frequency of Recurrence of Mitral Regurgitation After Ring Annuloplasty for Ischemic Mitral Regurgitation
Mitral Gradients and Frequency of Recurrence of Mitral Regurgitation After Ring Annuloplasty for Ischemic Mitral Regurgitation Matthew L. Williams, MD, Mani A. Daneshmand, MD, James G. Jollis, MD, John
More informationReconstruction of the intervalvular fibrous body during aortic and
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body: An analysis of clinical outcomes Nilto C. De Oliveira, MD Tirone E. David, MD Susan Armstrong, MSc Joan Ivanov,
More informationDr.ssa Loredana Iannetta. Centro Cardiologico Monzino
Dr.ssa Loredana Iannetta Centro Cardiologico Monzino Bicuspid aortic valve BAV is the most common congenital cardiac anomaly. Estimated incidence is 2% in general population. 4:1 male predominance. Frequency
More informationTAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationPersistent Tricuspid Regurgitation After Tricuspid Annuloplasty During Redo Valve Surgery Affects Late Survival and Valve-Related Events
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Advance Publication by-j-stage Persistent Tricuspid Regurgitation After Tricuspid Annuloplasty During Redo
More informationCopyright by ICR Publishers 2014
Comprehensive Hemodynamic Performance and Frequency of Patient-Prosthesis Mismatch of the St. Jude Medical Trifecta Bioprosthetic Aortic Valve Ajay Yadlapati 1, Jimmy Diep 3, Mary-Jo Barnes 2, Tristan
More informationCase. 15-year-old boy with bicuspid AV Severe AR with moderate AS. Ross vs. AVR (or AVP)
Case 15-year-old boy with bicuspid AV Severe AR with moderate AS Ross vs. AVR (or AVP) AMC case 14-year-old boy with bicuspid AV Severe AS with mild AR Body size Bwt: 55 kg, Ht: 154 cm, BSA: 1.53 m 2 Echocardiography
More informationInfluence of patient gender on mortality after aortic valve replacement for aortic stenosis
Influence of patient gender on mortality after aortic valve replacement for aortic stenosis Jennifer Higgins, MD, W. R. Eric Jamieson, MD, Osama Benhameid, MD, Jian Ye, MD, Anson Cheung, MD, Peter Skarsgard,
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationStainless Steel. Cobalt-chromium
Sapien is better than Corevalve! Raj R. Makkar, MD Associate Director, Cedars-Sinai Heart Institute Associate Professor, UCLA School of Medicine, Los Angeles Eberhard Grube: Pioneer in the field of TAVR
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informationPARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*
More informationResults of Transfemoral Transcatheter Aortic Valve Implantation
Results of Transfemoral Transcatheter Aortic Valve Implantation Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationSuccessful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement
Advanced Studies in Medical Sciences, Vol. 2, 2014, no. 1, 37-45 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/asms.2014.31213 Successful Transfemoral Edwards Sapien Aortic Valve Implantation
More informationImaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013
Imaging in TAVI Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston Scientific, St Jude, BMS imaging, GE Healthcare,
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationSevere left ventricular dysfunction and valvular heart disease: should we operate?
Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict
More informationEarly and One-year Outcomes of Aortic Root Surgery in Marfan Syndrome Patients
Early and One-year Outcomes of Aortic Root Surgery in Marfan Syndrome Patients A Prospective, Multi-Center, Comparative Study Joseph S. Coselli, Irina V. Volguina, Scott A. LeMaire, Thoralf M. Sundt, Elizabeth
More informationAlec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France
Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat
More informationTAVI IN BICUSPID AOV AND VALVE-IN-VALVE
TAVI IN BICUSPID AOV AND VALVE-IN-VALVE Petros S. Dardas, MD, FESC St Lukes Hospital Thessaloniki, GREECE 6o ΣΥΝΕΔΡΙΟ ΔΙΑΚΑΘΕΤΗΡΙΑΚΗΣ ΘΕΡΑΠΕΙΑΣ ΚΑΡΔΙΑΚΩΝ ΒΑΛΒΙΔΟΠΑΘΕΙΩΝ ΑΘΗΝΑ 2017 BICUSPID AOV Surgical
More informationProf. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation
Prof. Dr. Thomas Walther TAVI in ascending aorta / aortic root dilatation nn AorticStenosis - Guidelines TAVI and aortic aneurysm? Few data published. EJCTS 2014;46:228-33 TAVI and aortic aneurysm? Few
More informationPortico (St. Jude Medical Inc, St.
Review Article Portico Transcatheter Heart Valve Apostolos Tzikas 1,2, Michael Chrissoheris 2, Antonios Halapas 2, Konstantinos Spargias 2 1 Interbalkan European Medical Centre, Thessaloniki, 2 Hygeia
More informationPPM: How to fit a big valve in a small heart
PPM: How to fit a big valve in a small heart Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC King Abdulaziz Cardiac Centre National Guard Health Affairs Riyadh, Saudi Arabia GHA meeting Muscat
More informationEdwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?
Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationMulticentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system
Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist
More informationWhich Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated?
Ann Thorac Cardiovasc Surg 2013; 19: 428 434 Online January 31, 2013 doi: 10.5761/atcs.oa.12.01929 Original Article Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationParis, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co-Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationManagement of High-Risk Patients With Aortic Stenosis and Coronary Artery Disease
Management of High-Risk Patients With Aortic Stenosis and Coronary Artery Disease Daniel Wendt, MD, Philipp Kahlert, MD, Tim Lenze, Markus Neuhäuser, MD, Vivien Price, Thomas Konorza, MD, Raimund Erbel,
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationValve prosthesis-patient mismatch (PPM) was first defined
Impact of Valve Prosthesis-Patient Mismatch on Short-Term Mortality After Aortic Valve Replacement Claudia Blais, BSc; Jean G. Dumesnil, MD; Richard Baillot, MD; Serge Simard, MS; Daniel Doyle, MD; Philippe
More informationSotirios N. Prapas, M.D., Ph.D, F.E.C.T.S.
CORONARY ARTERY REVASCULARIZATION WITH MILD AORTIC STENOSIS: STRATEGIES OF TREATMENT 9 th ANNUAL MEETING OF THE EAB SOCIETY, Pravets, Bulgaria, 2012 Sotirios N. Prapas, M.D., Ph.D, F.E.C.T.S. Director
More information